Tigemonam activity against clinical isolates of Enterobacteriaceae and Enterobacteriaceae with known mechanisms of resistance to beta-lactam antibiotics.
Tigemonam, a new oral monobactam, was at least as active as aztreonam or carumonam against clinical isolates of Enterobacteriaceae (MIC90:0.06-16 mg/l). Tigemonam was very stable in the presence of classical plasmid mediated beta-lactamases but its MICs were increased (4-256 mg/l) in the presence of new broad-spectrum plasmid mediated beta-lactamases (either TEM of SHV derivatives). Increased MICs (0.25-8 mg/l) were also observed for different isogenic mutants of Enterobacteriaceae, which either produced high levels of chromosome-encoded cephalosporinases, or had a permeability defect.
Nélet
F
F
Laboratoire de Microbiologie Médicale, Hôpital Saint-Joseph, Paris, France.
Gutmann
L
L
Kitzis
M D
MD
Acar
J F
JF
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000302:isolation & purification; D004926:Escherichia coli / Q000187:drug effects; D007709:Klebsiella / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D008997:Monobactams / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D008997:Monobactams; C052020:tigemonam